Post-marketing clinical trial of Pegasys 180ug for subcutaneous injection (s.c.) in patients with chronic hepatitis C. -General clinical study in IFN-treated or IFN-untreated chronic hepatitis C patients, except for those infected with genotype 1b of hepatitis C virus and a high viral load.
Phase 4
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-jRCT1080220157
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Over 20 years old of male and female patients with chronic hepatitis C except for those infected with genotype 1b and a high viral load (>= 100 KIU/mL).And the patient shows positive serum HCV-RNA, and increase of serum ALT above the normal upper limit of the site.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety
- Secondary Outcome Measures
Name Time Method